Head-to-head · Value Score
bmiMD vs GoodRx
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, GoodRx a 74. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameGoodRx
#149 · Grade C+ · Watch List
Est. first month
From $149/mo (brand Foundayo)
The verdict
bmiMD takes it on Value Score, 89 to 74 — an est. $99/mo first month, with no teaser step-up baked in. GoodRx isn't out of it: Shoppers who want self-pay brand-name Foundayo and Zepbound KwikPen at retail pharmacies.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | GoodRx |
|---|---|---|
| Value Score | 89 (A) | 74 (C+) |
| Est. first month | $99/mo | From $149/mo (brand Foundayo) |
| Save vs brand-name | ~93% | — |
| Semaglutide | $99/mo | Not disclosed |
| Tirzepatide | $139/mo | From $299/mo (brand Zepbound) |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | All 50 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
GoodRx
GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.
Why it's a deal
- $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
- $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
- Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
- No membership fee — bring your own prescription and present the discount card at the pharmacy counter
- Brand-name FDA-approved medication, not compounded
The fine print
- Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
- Self-pay only — does not apply toward insurance benefits or deductibles
- Headline price applies to the lowest Foundayo dose; higher doses may cost more
- No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
- Pricing can change as Lilly's manufacturer coupon program evolves
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to GoodRx.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.